AI GRAND ROUNDS

Authors: GEMINI(RESIDENT), GROK(ATTENDING), CHATGPT (EXPERT) & ANUPAM SINGH MD(Human in loop)

Department of Medicine, Santosh Medical College.

Click here for App | Agentic Grand Rounds Index

Round 1

User:

Stage 1: History
A 25-year-old woman from New Delhi with a past medical history of depression, known mitral-valve prolapse (MVP), and migraine headaches presents to the emergency department with a 3-day history of subjective fevers, diffuse arthralgias, and a severe generalized headache. She states that the headache is distinct in character and intensity from her usual migraines.

Past Medical & Surgical History: History of depression, mitral-valve prolapse diagnosed in adolescence, and episodic migraine headaches. No history of autoimmune disease, recent travel, or intravenous drug use.
Medications: Baseline therapy for depression and migraine prophylaxis.
Review of Systems: No focal weakness, numbness, sensory deficits, neck stiffness, photo/phonophobia, skin rash, or active joint swelling.

Resident:

Hello, Chief Resident here.

Key Findings:
A 25-year-old woman from New Delhi presents with an acute 3-day history of fevers, diffuse arthralgias, and a severe, atypical headache, on a background of mitral valve prolapse (MVP).

Differential Diagnoses:
1. Arboviral Infection (Dengue / Chikungunya) – 40%: Highly endemic in New Delhi; classic presentation of acute fever, severe headache, and "breakbone" arthralgias.
2. Infective Endocarditis (IE) – 25%: Unexplained fever, systemic arthralgias, and severe headache in a patient with underlying MVP necessitate ruling out subacute bacterial endocarditis.
3. Other Endemic Tropical Infections (Malaria / Typhoid) – 20%: Prevalent regional febrile illnesses causing acute systemic symptoms.
4. Acute Viral Illness with Secondary Atypical Headache – 15%: Systemic viral infection triggering a distinct headache, though fever/arthralgias require underlying infection workup.

Recommended Prioritized Tests:
1. CBC with Peripheral Blood Smear: Evaluate for thrombocytopenia, leukopenia, and malarial parasites.
2. Dengue NS1 Antigen & IgM/IgG Serology: Direct diagnostic testing for dengue.
3. Blood Cultures (3 sets from different sites): Essential to rule out bacteremia and IE given structural heart history.
4. Transthoracic Echocardiogram (TTE): Evaluate valvular anatomy and rule out vegetations.
5. Malaria Rapid Diagnostic Test (RDT) & Blood Smear.

Attending:

Hello Attending Consultant here

Critique: Solid endemic focus and IE consideration given MVP, but underweights CNS complications (e.g., septic emboli/meningitis) and omits inflammatory markers/LP thresholds. TTE first-line is appropriate yet low-sensitivity; plan lacks acuity staging.

Top 3 DDx:
1. Infective endocarditis (MVP + fever/arthralgia/headache)
2. Arboviral (dengue/chikungunya)
3. Cerebral malaria / enteric fever

Specific points:
1. Obtain 3 blood cultures pre-antibiotics; add fungal if prolonged.
2. Urgent TTE → low threshold for TEE.
3. CBC, smear, NS1/IgM, malaria RDT/thick-thin films STAT.
4. ESR/CRP, RF, ANA to screen mimicry.
5. Neuroimaging + LP if headache worsens or meningismus emerges.
6. Hold empiric abx pending cultures unless septic.
7. Serial neuro checks; migraine prophylaxis irrelevant acutely.

Expert:

Hello, Expert Clinician here.

Best current unifying diagnosis: Infective endocarditis involving the abnormal mitral valve, with possible neurologic complication (septic embolus, meningitis, or intracranial/mycotic aneurysm). This remains provisional; the history alone is insufficient to diagnose IE.

Top differentials
- Dengue/chikungunya: New Delhi exposure, acute fever, headache, and arthralgias fit. Chikungunya usually causes prominent joint pain; dengue often causes cytopenias, myalgias, or retro-orbital pain. Neither explains the valvular risk.
- Malaria or enteric fever: Epidemiologically plausible, but the symptom pattern is less characteristic; malaria requires repeated thick/thin smears if initially negative.
- Acute meningitis/encephalitis: Fever plus a new severe headache warrants consideration despite absent meningismus, which does not reliably exclude meningitis.
- Primary migraine: Poor fit because this headache is distinctly different and accompanied by systemic symptoms.

Key pivot: A severe headache unlike her usual migraines is a secondary-headache red flag, especially alongside fever and structural valve disease.

Next move: Obtain three blood-culture sets before antibiotics while urgently evaluating the headache with neurologic examination and brain imaging (CT, with CTA/MRI as indicated). Then perform CBC/platelets, malaria and dengue/chikungunya testing, and TTE followed by TEE if suspicion persists.

Teaching pearl: MVP alone confers modest IE risk, but fever plus new neurologic symptoms should trigger an embolic-complication search.

Round 2

User:

Stage 2: Exam + Initial Workup
Physical Examination:
Vitals: Afebrile at initial evaluation, Pulse 120 beats/min (sinus tachycardia), BP 98/41 mmHg, Respiratory Rate 18/min, SpO2 98% on room air.
General: Somnolent but easily arousable with normal mentation.
Neurologic: Cranial nerves intact, motor strength 5/5 in all extremities, intact sensation, no nuchal rigidity or meningeal signs.
Cardiovascular: Tachycardic; a Grade 2/6 systolic murmur is audible at the left sternal border. Normal S1/S2, no pericardial rub. Lungs clear to auscultation. No active joint inflammation, petechiae, or rash.

Laboratory Investigations:
- Complete Blood Count: WBC 6,600/µL (66% segmented neutrophils, 17% band neutrophils [left shift]), Hemoglobin 9.7 g/dL (normocytic, MCV 84 fL), Reticulocyte count 6,000/µL (low/inadequate). Platelet count: 22,000/µL (Severe Thrombocytopenia).
- Coagulation Profile: INR 1.0, aPTT 22.2 seconds (Normal).
- Metabolic Panel: Serum Creatinine 0.8 mg/dL (71 µmol/L), Blood Urea Nitrogen 12 mg/dL, Electrolytes normal. Serum Albumin 1.9 g/dL (Low).

Initial Interventions & Lumbar Puncture:
- Empirical IV antibiotic therapy (doxycycline, ceftriaxone, gentamicin) was administered prior to obtaining microbial blood cultures.
- Head CT: Normal without hemorrhage or mass lesion.
- Lumbar Puncture: Normal opening pressure. CSF glucose 80 mg/dL, protein 46 mg/dL, WBC 1/µL, RBC 7/µL. Gram stain negative.
- Initial blood, CSF, and urine cultures showed no growth, leading to antibiotic discontinuation.

Resident:

Hello, Chief Resident here.

Updated Key Findings:
Severe thrombocytopenia (22,000/µL), normocytic anemia with low reticulocytes, left shift (17% bands), marked hypoalbuminemia (1.9 g/dL), somnolence, and sinus tachycardia, with normal LP/Head CT and sterile post-antibiotic cultures.

Differential Diagnoses:
1. Severe Dengue Fever – 60%: Endemic exposure, classic presentation, profound thrombocytopenia, marked capillary leak (hypoalbuminemia), and somnolence (severe dengue warning sign).
2. Culture-Negative Infective Endocarditis – 25%: MVP background, new/changing systolic murmur, and left shift; cultures likely suppressed by pre-culture antibiotics.
3. Scrub Typhus / Chikungunya Co-infection – 10%: Prevalent in New Delhi, presenting with severe microvascular leak, cytopenias, arthralgias, and altered sensorium.
4. Thrombotic Microangiopathy (TTP/HUS) – 5%: Acute thrombocytopenia, anemia, and altered mental status, though normal coags and low reticulocytes make classic DIC or hemolysis less probable.

Prioritized Next Steps:
1. Dengue NS1 Antigen, IgM/IgG Serology, and PCR.
2. Echocardiogram (TTE, followed by TEE if unrevealing): Crucial to evaluate MVP for vegetations.
3. Peripheral Blood Smear: Evaluate for malarial parasites and schistocytes.
4. Serology for Culture-Negative IE (Coxiella, Bartonella, Brucella).
5. Scrub Typhus IgM Serology.

Attending:

Hello Attending Consultant here

Critique: Strong pivot to severe dengue given leak physiology and cytopenias, but underemphasizes iatrogenic culture sterilization and hemodynamic instability (wide pulse pressure, tachycardia). TMA ranking too low; omits quantitative dengue PCR and fluid-resuscitation endpoints. Echo timing appropriate yet delayed relative to embolic risk.

Top 3 DDx:
1. Severe dengue (plasma leakage + thrombocytopenia + encephalopathy)
2. Pretreated culture-negative IE (MVP + murmur + bands)
3. Scrub typhus / rickettsial with secondary HIT-like picture

Specific points:
1. STAT dengue NS1/PCR + paired serology; serial Hct for leak.
2. Immediate TTE→TEE; add Bartonella/Coxiella serologies.
3. Peripheral smear + ADAMTS13 to exclude TTP.
4. Restrictive fluids, monitor for shock; avoid NSAIDs/IM shots.
5. Platelet transfusion only if bleeding or pre-procedure.
6. Repeat blood cultures off antibiotics; hold further empiric Rx.
7. Continuous neuro/hemodynamic q1h checks; ICU if worsening leak.

Expert:

Hello, Expert Clinician here.

Best current unifying diagnosis: Pretreated culture-negative infective endocarditis with systemic inflammatory illness and possible neurologic involvement. MVP/murmur, hypotension, tachycardia, bandemia, anemia, thrombocytopenia, and hypoalbuminemia support serious infection. Cultures obtained after antibiotics cannot reliably exclude IE.

Top differentials
- Severe dengue: Fever, arthralgias, headache, profound thrombocytopenia, and possible plasma leakage fit. However, anemia rather than hemoconcentration, bandemia, and murmur weaken this diagnosis.
- Scrub typhus/other rickettsiosis: Endemic exposure, thrombocytopenia, headache, and shock fit; absence of rash or eschar does not exclude it.
- TTP: Thrombocytopenia plus neurologic symptoms and normal coagulation tests warrant exclusion, but inadequate reticulocytosis and no documented schistocytes, elevated LDH, or renal injury argue against active microangiopathic hemolysis.
- Malaria: Must be tested regionally, although the current pattern is nonspecific.

Key pivot: Negative cultures are uninterpretable because broad antibiotics preceded collection; stopping therapy solely for this reason risks missed IE.

Next move: Urgent TTE followed promptly by TEE, repeat multiple blood cultures off antibiotics if stable, and obtain smear/LDH/haptoglobin, dengue NS1/PCR, malaria films, and Coxiella/Bartonella/Brucella testing. Hemodynamic instability warrants monitored resuscitation and empiric IE therapy after cultures.

Teaching pearl: Lumbar puncture at 22,000 platelets carries substantial bleeding risk.

Round 3

User:

Stage 3: MAHA Findings, TTP Diagnosis & Initial Response
Laboratory Evaluation of Anemia & Thrombocytopenia:
- Peripheral Blood Smear: Revealed markedly reduced platelets and scattered schistocytes (microangiopathic hemolytic anemia).
- Hemolysis & Coagulation Markers:
- Fibrinogen: 360.2 mg/dL (Normal 183–434).
- D-dimer: 1.25 µg/mL (Elevated; normal <0.25).
- Lactate Dehydrogenase (LDH): 748 U/L (Elevated; normal 200–600).
- Serum Haptoglobin: <5 mg/dL (Severely decreased; normal 37–264).

Initial Diagnosis & Plasma Exchange Therapy:
Given microangiopathic hemolytic anemia (MAHA) and severe thrombocytopenia (22,000/µL), a presumptive diagnosis of Thrombotic Thrombocytopenic Purpura (TTP) was made. Therapeutic Plasma Exchange (PEX) and high-dose IV corticosteroids were initiated.
Response: The patient improved clinically, and her platelet count progressively recovered to >300,000/µL.

Intercurrent Events & Autoimmune Evaluation:
- Hospital Day 5: Patient developed right-sided pleuritic chest pain. Chest radiograph showed a right-sided pleural effusion; thoracentesis yielded transudative fluid (pH 7.53, LDH 361 U/L, protein <2 g/dL, glucose 86 mg/dL).
- Patient recalled a transient facial/limb rash and sore throat several weeks prior to admission.
- Autoimmune Serology: Antinuclear Antibody (ANA) positive at 1:160 titer; Rheumatoid Factor (RF) positive at 185 IU/mL (normal <35). Urinalysis: 1+ protein, 1+ blood.
- Discharge: Discharged on Day 8 on oral corticosteroids with presumed TTP responsive to PEX and possible underlying Systemic Lupus Erythematosus (SLE).

Resident:

Hello, Chief Resident here.

Updated Key Findings:
Proven MAHA (schistocytes, elevated LDH, undetectable haptoglobin) and severe thrombocytopenia that dramatically responded to PEX/steroids. Evolution of pleuritis with effusion, microhematuria, proteinuria, positive ANA/RF, and recalled facial rash strongly point to systemic autoimmunity.

Differential Diagnoses:
1. Secondary TTP triggered by Systemic Lupus Erythematosus (SLE) – 75%: Clinical pentad (fever, MAHA, severe thrombocytopenia, transient somnolence) alongside pleuritis, proteinuria, positive ANA, and rapid response to PEX/immunosuppression fits SLE-driven severe ADAMTS13 deficiency or severe microangiopathy.
2. Systemic Lupus Erythematosus (SLE) with Evans Syndrome / Lupus Nephritis – 15%: Autoimmune hemolytic anemia and immune thrombocytopenia with serositis and renal involvement, though prominent schistocytes heavily favor a thrombotic microangiopathy mechanism.
3. Secondary Antiphospholipid Syndrome (aPL / CAPS) – 10%: Can manifest as MAHA, serositis, and autoantibody positivity in underlying SLE.

Recommended Prioritized Tests:
1. ADAMTS13 Activity & Inhibitor Titer: Confirm underlying TTP mechanism (<10% activity).
2. Comprehensive SLE Serologies & Complements: anti-dsDNA, anti-Sm, anti-SSA/SSB, and C3/C4 levels.
3. Antiphospholipid Panel: Lupus anticoagulant, anticardiolipin, anti-β2-glycoprotein I.
4. Spot Urine Protein-to-Creatinine Ratio (UPCR): Quantify renal involvement for lupus nephritis staging.
5. Rheumatology Follow-up: Initiate Hydroxychloroquine and steroid-sparing maintenance therapy.

Attending:

Hello Attending Consultant here

Critique: Correct SLE-TTP linkage and PEX response, but overstates “pentad,” underweights CAPS vs ADAMTS13 TTP, and omits urgent aPL/complement timing plus infection exclusion before prolonged steroids. Effusion workup incomplete; no echo recheck for Libman-Sacks.

Top 3 DDx:
1. SLE-associated TTP (ADAMTS13 deficiency)
2. Catastrophic APS / SLE-TMA
3. Infection-triggered secondary TMA (post-strep/viral) unmasking SLE

Specific points:
1. STAT ADAMTS13 activity/inhibitor pre-further PEX.
2. Full aPL panel + C3/C4, anti-dsDNA/Sm immediately.
3. Repeat blood cultures/serologies; hold escalation if infection possible.
4. Quantify proteinuria; early renal biopsy if rising Cr/UPCR.
5. TEE to exclude Libman-Sacks/IE vegetations.
6. Add HCQ; consider rituximab if ADAMTS13 inhibitor confirmed.
7. Thromboprophylaxis once platelets >50k; monitor for CAPS.

Expert:

Hello, Expert Clinician here.

Best current unifying diagnosis: Acquired immune TTP, potentially secondary to SLE or occult infection. MAHA, profound thrombocytopenia, neurologic symptoms, normal coagulation studies, and rapid response to plasma exchange strongly support TTP, but confirmation requires ADAMTS13 activity <10% with inhibitor.

Top differentials
- SLE-associated thrombotic microangiopathy: Rash history, pleuritis, ANA, cytopenias, and urinary abnormalities fit. However, ANA/RF are nonspecific, and SLE is not yet established without anti-dsDNA/Sm, complement levels, and quantified renal disease.
- Infection-associated TMA/endocarditis: MVP/murmur, bandemia, hypotension, low albumin, and cultures sterilized by prior antibiotics remain concerning. IE can cause positive RF/ANA and mimic autoimmune disease.
- Catastrophic antiphospholipid syndrome: Consider if multiorgan thrombosis emerges, but no documented thromboses or persistent antiphospholipid antibodies currently support it.
- DIC: Unlikely with normal INR/aPTT and fibrinogen.

Key pivot: PEX response establishes a treatable TMA phenotype but does not identify its cause.

Next move: Urgently obtain ADAMTS13 activity/inhibitor, complements, dsDNA/Sm, antiphospholipid panel, UPCR, repeat pre-antibiotic blood cultures, and TTE/TEE. Continue TTP-directed therapy until durable remission; consider caplacizumab/rituximab if immune TTP is confirmed.

Teaching pearl: Positive ANA and RF can occur in infective endocarditis—never equate seropositivity alone with SLE.

Round 4

User:

Stage 4: Relapse, Bacteremia & Cardiac Echocardiography
Relapse Presentation:
Five days after discharge, the patient presented back to the ED with recurrent severe headache and emesis.
Physical Exam: Afebrile, BP 110/70 mmHg, HR 100 bpm. No nuchal rigidity or focal deficits.
Labs: WBC 7,700/µL, Hb 8.6 g/dL, Platelets 136,000/µL. However, next-day repeat smear showed platelets plummeting back to 23,000/µL (without schistocytes). PEX was reinitiated.

Microbiologic Discovery:
- Repeat blood cultures obtained prior to antibiotic restart grew β-hemolytic Group C Streptococcus in multiple blood culture bottles.
- Targeted therapy with IV Ceftriaxone was initiated.

Cardiac Imaging:
- Transthoracic Echocardiogram (TTE): LVEF 65%, myxomatous mitral valve leaflets with anterior leaflet prolapse and severe mitral regurgitation (MR). No clear vegetation visualised.
- Transesophageal Echocardiogram (TEE): Demonstrated ruptured chordae tendineae of the mitral valve, anterior leaflet perforation, posterior leaflet thickening, and severe mitral regurgitation.

Resident:

Resident:
Hello, Chief Resident here.

Updated Key Findings:
Refractory/relapsed severe thrombocytopenia, recurrent severe headache, Group C Streptococcus bacteremia, and TEE confirmation of mitral valve destruction (anterior leaflet perforation, ruptured chordae tendineae, severe MR).

Differential Diagnoses:
1. Infective Endocarditis (Group C Streptococcus) with Secondary Infection-Induced Thrombotic Microangiopathy / Immune Thrombocytopenia – 85%: Valvular perforation and ruptured chordae on TEE confirm definitive IE (Duke Criteria). Bacterial-induced endothelial injury and immune-complex deposition explain the severe TMA/thrombocytopenia mimicking TTP.
2. Systemic Lupus Erythematosus (SLE) with Libman-Sacks Endocarditis & Secondary IE – 10%: Underlying SLE predisposing to bacterial seeding, though valve perforation heavily points to acute destructive bacterial endocarditis.
3. Primary Immune TTP complicated by Nosocomial/Opportunistic Bacteremia – 5%: Relapse of true TTP concurrent with bacterial sepsis following PEX access/steroid immunosuppression.

Prioritized Next Steps:
1. Urgent Cardiac Surgery Consultation: Mitral valve repair/replacement for native valve perforation and acute heart failure/severe MR.
2. Continue Targeted IV Ceftriaxone: Minimum 4–6 weeks for streptococcal endocarditis.
3. Repeat ADAMTS13 Activity & Inhibitor: Differentiate true TTP from infection-induced secondary TMA to guide PEX duration.
4. Repeat Serial Blood Cultures: Ensure clearance of Group C Streptococcus.
5. Brain MRI / MRA: Rule out embolic stroke, mycotic aneurysm, or intracranial abscess explaining recurrent severe headaches.

Attending:

Hello Attending Consultant here

Critique: Excellent diagnosis of GCS endocarditis with structural destruction; correct surgical pivot. Understates secondary TMA mechanisms vs true TTP and misprioritizes MRI over immediate surgical clearance/culture clearance. PEX continuation without ADAMTS13 target needs caution.

Top 3 DDx:
1. Group C Streptococcal infective endocarditis with infection-driven TMA/ITP
2. IE-induced SLE/APS mimicry with valvular destruction
3. True relapsed TTP with catheter-related/secondary GCS bacteremia

Specific points:
1. Urgent cardiothoracic surgery consult for valve repair/replacement.
2. Continue IV Ceftriaxone (or penicillin + gentamicin per sensitivities).
3. STAT ADAMTS13 test pre-further PEX; stop PEX if activity >10%.
4. Daily blood cultures until clear; screen for metastatic foci.
5. Brain MRI/MRA for embolic/mycotic aneurysm source of headache.
6. Quantify MR/hemodynamics; ICU monitoring for acute decompensation.
7. Discontinue immunosuppression unless autoimmune disease confirmed.

Expert:

Hello, Expert Clinician here.

Best current unifying diagnosis: Definite Infective Endocarditis caused by β-hemolytic Group C Streptococcus, complicated by severe structural valve damage (leaflet perforation, chordal rupture, severe MR) and infection-triggered thrombotic microangiopathy or severe immune thrombocytopenia mimicking TTP.

Top differentials
- Infection-induced TMA / sepsis-associated cytopenia: GCS endocarditis induces severe endothelial activation and immune complex consumption. The absence of schistocytes during relapse supports secondary immune thrombocytopenia or endothelial injury over classic ADAMTS13-deficient TTP.
- Relapsed Primary TTP with central line or intercurrent GCS bacteremia: Possible given initial response to PEX, but GCS is an unusual line pathogen and structural valve destruction better explains the entire severe illness course.
- SLE with Libman-Sacks endocarditis and secondary infection: IE can mimic SLE serologically; destructive perforation heavily favors primary bacterial endocarditis over pure nonbacterial verrucous endocarditis.

Key pivot: TEE findings of leaflet perforation and chordal rupture establish native-valve endocarditis regardless of initial negative cultures.

Next move: Urgent cardiothoracic surgery evaluation for valve replacement/repair, maintain IV Ceftriaxone, check ADAMTS13 activity to decide whether to stop PEX, obtain daily blood cultures until sterile, and perform brain MRI/MRA to exclude embolic or mycotic neurovascular complications.

Teaching pearl: Prior antibiotics mask cultures and delay IE diagnosis; infection-driven endothelial damage frequently simulates autoimmune hematologic conditions like TTP.

Attending:

Hello Attending Consultant here

Critique: Accurate IE confirmation via TEE destruction and GCS bacteremia; surgical urgency correct. Overweights primary TTP residual risk and delays source control; underemphasizes embolic workup timing and antibiotic optimization per MIC. PEX reinitiation without ADAMTS13 risks unnecessary exposure.

Top 3 DDx:
1. Definite GCS native-valve IE with secondary TMA/ITP
2. IE unmasking SLE/Libman-Sacks + superinfection
3. Relapsed immune TTP + secondary bacteremia

Specific points:
1. Immediate CTS consult for MV repair/replacement (perforation + severe MR).
2. Tailor abx to sensitivities (CTX ± gentamicin synergy); 4–6 wk course.
3. Hold further PEX pending STAT ADAMTS13; discontinue if >10%.
4. Daily cultures to document clearance; PET/CT if persistent bacteremia.
5. Urgent brain MRI/MRA for mycotic aneurysm/emboli given headache.
6. Serial TTE for MR progression/heart failure; ICU monitoring.
7. Stop steroids/HCQ unless dsDNA/complements confirm SLE.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: Group C β-hemolytic streptococcal native mitral-valve infective endocarditis, causing destructive valve disease—leaflet perforation, chordal rupture, and severe MR—with infection-associated thrombotic microangiopathy/immune thrombocytopenia that initially mimicked TTP.

Top differentials
- Acquired immune TTP: Initial MAHA and PEX response fit, but recurrent thrombocytopenia without schistocytes and discovery of destructive IE favor an infection-driven process. ADAMTS13 activity/inhibitor is decisive, although results after PEX may be unreliable.
- SLE/Libman–Sacks endocarditis with superinfection: Rash, ANA, pleuritis, and urinary findings are suggestive; however, RF/ANA can accompany IE, and bacteremia plus valve perforation strongly supports bacterial endocarditis.
- DIC: Unlikely given preserved coagulation studies and fibrinogen.

Key pivot: Multiple pre-antibiotic cultures growing Group C Streptococcus plus destructive TEE findings overturn the earlier culture-negative TTP/SLE framing.

Next move: Obtain urgent cardiothoracic surgery consultation for early mitral repair/replacement, continue susceptibility-directed IV ceftriaxone for 4–6 weeks, and repeat cultures until sterile. Because of recurrent atypical headache, obtain urgent brain MRI with vascular imaging to exclude emboli or mycotic aneurysm before surgery. Reassess PEX/steroids using ADAMTS13 and current hemolysis evidence.

Teaching pearl: IE may produce MAHA and autoimmune serologies; source control—not escalating immunosuppression—is definitive.

Round 5

User:

Stage 5: Final Results & Clinical Outcome
Neuroimaging & Surgical Management:
- Brain MRI: Revealed multiple increased T2/FLAIR hyperintense signals in bilateral cerebral hemispheres consistent with embolic cerebral infarctions.
- Diagnosis Established: Infective Endocarditis fulfilling Modified Duke Criteria (Group C Streptococcal bacteremia, predisposing MVP with severe MR and chordal rupture/perforation, positive RF, and embolic brain infarctions).

Surgical Intervention & Histopathology:
- Hospital Day 10: Patient underwent emergency cardiac surgery with mitral valve replacement using a bioprosthetic valve.
- Intraoperative Inspection: Confirmed myxomatous degeneration, ruptured chordae tendineae, and anterior mitral leaflet perforation.
- Valve Tissue Histopathology & Gram Stain: Showed acute fibrinous and organizing inflammation with polypoid tufts, heavy neutrophil infiltration, and clusters of Gram-positive cocci, confirming acute infective endocarditis.

Final Unifying Diagnosis:
Group C Streptococcal Infective Endocarditis masquerading as Thrombotic Thrombocytopenic Purpura (TTP) and Systemic Lupus Erythematosus (SLE), causing microangiopathic hemolytic anemia, severe thrombocytopenia, mitral chordal rupture, and embolic brain infarctions.

Post-Operative Outcome:
The patient completed a 6-week course of IV Ceftriaxone. She made a full recovery with normalization of platelet counts, complete resolution of neurological symptoms, and normal prosthetic valve function without long-term sequelae.

Resident:

Hello, Chief Resident here.

Updated Key Findings:
Bilateral embolic cerebral infarctions on MRI, intraoperative confirmation of mitral leaflet perforation/chordal rupture, histopathological proof of Gram-positive cocci, and complete hematologic recovery following bioprosthetic valve replacement and 6 weeks of IV ceftriaxone.

Final Diagnosis:
1. Group C Streptococcal Infective Endocarditis with Secondary Microangiopathic Hemolytic Anemia / Autoimmune Mimicry – 100%: Confirmed via surgical histopathology, microbiology, Duke criteria (bacteremia, valvular destruction, cerebral emboli, positive RF), and full clinical cure after surgery and targeted antibiotics.

Case Analysis:
This case demonstrates how acute infective endocarditis can masquerade as primary TTP and SLE via severe endothelial activation, immune complex deposition (false-positive ANA/RF), and embolic stroke causing an atypical severe headache. Pre-culture antibiotics transiently sterilized initial blood cultures, delaying definitive diagnosis.

Next Steps & Management:
1. Post-Operative Surveillance: Routine outpatient TTE at 3–6 months to assess bioprosthetic valve function.
2. Prophylaxis: Educate patient on lifetime antibiotic prophylaxis prior to dental and invasive procedures.
3. Outpatient Autoimmune Re-evaluation: Re-check ANA, RF, and urinalysis in 3–6 months off immunosuppression to document resolution of secondary autoimmune features.

Attending:

Hello Attending Consultant here

Critique: Accurate final unification of GCS IE as TTP/SLE mimic via Duke criteria, histopathology, and emboli; recovery validates source control. Overstates 100% certainty without residual ADAMTS13 data; post-op plan lacks endocarditis prophylaxis timing, dental clearance, and surveillance for prosthetic complications or late autoimmune flare.

Top 3 DDx:
1. Definite GCS native-valve IE with secondary TMA/ITP (confirmed)
2. IE unmasking latent SLE/Libman-Sacks
3. Primary TTP with secondary bacteremic seeding (excluded by histo)

Specific points:
1. Confirm 6-wk IV CTX completion; switch to oral only if intolerant.
2. Lifelong IE prophylaxis pre-dental/invasive procedures.
3. Serial TTE at 1/3/6 mo for prosthetic function/paravalvular leak.
4. Repeat ADAMTS13 off PEX to exclude residual inhibitor.
5. Reassess ANA/RF/complements/UPCR at 3 mo off steroids.
6. Neuro follow-up + MRI if residual deficits; antiplatelet if indicated.
7. Dental evaluation + hygiene education to prevent recurrence.

Expert:

Hello, Expert Clinician here.

Final unifying diagnosis: Group C β-hemolytic streptococcal native mitral-valve infective endocarditis, producing leaflet perforation, chordal rupture, severe MR, and cerebral septic emboli, with infection-associated MAHA and thrombocytopenia masquerading as TTP and SLE. Valve histology showing neutrophilic inflammation and Gram-positive cocci definitively confirms IE.

Key differentials
- Immune TTP: Initial MAHA, thrombocytopenia, neurologic symptoms, and apparent PEX response fit; however, relapse without schistocytes and sustained recovery after valve replacement/antibiotics favor secondary TMA. A pretreatment ADAMTS13 level would have been decisive.
- SLE/Libman–Sacks endocarditis: ANA, RF, rash, serositis, and urinary abnormalities suggested SLE, but IE itself can generate immune-complex findings and positive autoantibodies. Destructive infected valve pathology excludes isolated Libman–Sacks disease.
- DIC: Inconsistent with normal coagulation tests and fibrinogen.

Key pivot: Pre-antibiotic Group C streptococcal cultures plus destructive TEE findings and embolic MRI lesions overturned the TTP/SLE framing.

Most important ongoing move: Complete antimicrobial therapy and maintain prosthetic-valve surveillance, dental hygiene, and guideline-based IE prophylaxis for qualifying dental procedures; reassess autoimmune markers and ADAMTS13 off PEX/steroids if clinically relevant.

Teaching pearl: Improvement with PEX does not prove TTP—always investigate its trigger, particularly occult endocarditis.

Top 15 Takeaways for Clinicians

    Top 15 Takeaways for Clinicians

    1. Infective endocarditis is one of the ultimate masqueraders in medicine. IE can present with microangiopathic hemolytic anemia, severe thrombocytopenia, positive autoantibodies (ANA, RF), and neurological deficits, mimicking TTP or SLE.
    2. Never give empirical antibiotics before drawing blood cultures. Administering broad-spectrum antibiotics prior to obtaining blood cultures sterilizes blood samples, resulting in "culture-negative" endocarditis and delaying definitive diagnosis.
    3. Response to Plasma Exchange (PEX) does not prove primary TTP. PEX can transiently improve platelet counts in infection-induced endothelial injury; clinicians must continue searching for underlying triggers like endocarditis.
    4. Infective endocarditis frequently induces false-positive autoantibodies. Circulating immune complexes in subacute endocarditis commonly trigger positive Antinuclear Antibody (ANA) and Rheumatoid Factor (RF) titers, misleading clinicians toward autoimmune disease.
    5. Mitral Valve Prolapse (MVP) is a major predisposing risk factor for endocarditis. Even in young adults, myxomatous valve degeneration increases vulnerability to bacterial colonization and chordal rupture.
    6. A new or changing cardiac murmur with fever demands echocardiography. In any febrile patient with structural heart disease or neurological symptoms, perform TTE followed by Transesophageal Echocardiography (TEE) to detect occult vegetations or leaflet perforation.
    7. Severe atypical headache in structural heart disease is a red flag. Any headache distinct from baseline migraines in a febrile patient with MVP suggests embolic cerebral infarctions or mycotic aneurysms.
    8. Always verify microangiopathic hemolysis before diagnosing TTP. Severe thrombocytopenia alone is insufficient for TTP; check blood smear for schistocytes, serum LDH, haptoglobin, and obtain ADAMTS13 testing.
    9. Lumbar puncture in severe thrombocytopenia carries high bleeding risk. Performing an LP at a platelet count of 22,000/µL increases the risk of spinal epidural hematoma; correct platelets or evaluate necessity first.
    10. Ruptured chordae tendineae and leaflet perforation require urgent cardiac surgery. Acute severe mitral regurgitation from infective valvular destruction is a surgical emergency requiring early valve repair or replacement.
    11. Repeat blood cultures off antibiotics are vital when suspicion remains high. Discontinuing empirical antibiotics and drawing multiple blood culture sets over 24-48 hours can unmask previously hidden bacteremia (e.g., Group C Streptococcus).
    12. Group C β-hemolytic Streptococcus can cause aggressive endocarditis. Although less common than viridans streptococci or Staph aureus, Group C streptococci can cause severe valvular destruction and systemic embolization.
    13. Central nervous system emboli occur in up to 30-40% of endocarditis cases. Brain MRI with T2/FLAIR sequences is essential to identify cerebral embolic lesions prior to cardiac surgery and anticoagulation decisions.
    14. Definitive cure of bacterial endocarditis requires targeted bactericidal therapy. A complete 4 to 6-week course of IV antibiotics (such as Ceftriaxone) is mandatory following valve replacement.
    15. Re-evaluate autoimmune serologies after infection clearance. Repeat ANA, RF, and inflammatory markers 3 to 6 months post-recovery to confirm normalization and rule out underlying connective tissue disease.